CAR-T
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
916
NCT03939026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: May 1, 2019
Completion: Aug 31, 2026
NCT04093596
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Start: Sep 23, 2019
Completion: Sep 30, 2027
NCT04416984
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Phase: Phase 1/2
Start: May 21, 2020
Completion: May 31, 2029
NCT04696731
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Start: Feb 24, 2021
Completion: Dec 31, 2025
NCT05000450
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Start: Jun 6, 2021
Completion: Oct 11, 2023
NCT05714345
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Phase: Phase 2
Start: Mar 31, 2023
Completion: Oct 31, 2029
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Start: Jun 18, 2024
Completion: Aug 24, 2031
NCT06925685
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
Phase: N/A
Start: Jan 31, 2025
Completion: Jan 31, 2039
NCT07085104
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Start: Sep 30, 2025
Completion: Oct 31, 2032
Loading map...